trending Market Intelligence /marketintelligence/en/news-insights/trending/X74Ny9-M0MBvIhzloGmSxg2 content esgSubNav
In This List

Calithera Biosciences breast cancer treatment progresses to phase 2 study

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Calithera Biosciences breast cancer treatment progresses to phase 2 study

Calithera Biosciences Inc. said the phase 1 study of CB-839, in combination with paclitaxel, showed responses in heavily pretreated patients with advanced/metastatic triple negative breast cancer, or TNBC.

Calithera said data from the trial exhibited tolerability of CB-839 and highlighted the "unique mechanism of action" of the therapy.

The combination treatment has been well-tolerated, with side effects that are primarily low-grade and reversible, including neutropenia — a blood condition wherein the level of a certain type of white blood cell drops.

Calithera has opened a phase 2 trial to further evaluate the combo in both first-line and late-line metastatic TNBC.